Literature DB >> 31830882

Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder.

Atefeh Amiri1, Maryam Mahjoubin-Tehran1, Zatollah Asemi2, Alimohammad Shafiee3, Sarah Hajighadimi3, Sanaz Moradizarmehri3, Hamid Reza Mirzaei4, Hamed Mirzaei2.   

Abstract

Cancer and inflammatory disorders are two important public health issues worldwide with significant socio.economic impacts. Despite several efforts, the current therapeutic platforms are associated with severe limitations. Therefore, developing new therapeutic strategies for the treatment of these diseases is a top priority. Besides current therapies, the utilization of natural compounds has emerged as a new horizon for the treatment of cancer and inflammatory disorders as well. Such natural compounds could be used either alone or in combination with the standard cancer therapeutic modalities such as chemotherapy, radiotherapy, and immunotherapy. Resveratrol is a polyphenolic compound that is found in grapes as well as other foods. It has been found that this medicinal agent displays a wide pharmacological spectrum, including anti-cancer, anti-inflammatory, anti-microbial, and antioxidant activities. Recently, clinical and pre-clinical studies have highlighted the anti-cancer and anti-inflammatory effects of resveratrol. Increasing evidence revealed that resveratrol exerts its therapeutic effects by targeting various cellular and molecular mechanisms. Among cellular and molecular targets that are modulated by resveratrol, microRNAs (miRNAs) have appeared as key targets. MiRNAs are short non-coding RNAs that act as epigenetic regulators. These molecules are involved in many processes that are involved in the initiation and progression of cancer and inflammatory disorders. Herein, we summarized various miRNAs that are directly/indirectly influenced by resveratrol in cancer and inflammatory disorders. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Resveratrol; cancer; microRNA; non-cancerous diseases; non-coding RNAs; therapy

Year:  2021        PMID: 31830882     DOI: 10.2174/0929867326666191212102407

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  Potential therapeutic targets and molecular details of anthocyan-treated inflammatory bowel disease: a systematic bioinformatics analysis of network pharmacology.

Authors:  Yuqi Lin; Lianxiang Luo; Haowen Lin; Xiaoling Li; Riming Huang
Journal:  RSC Adv       Date:  2021-02-22       Impact factor: 3.361

2.  IL-6 Promotes Hepatocellular Carcinoma Invasion by Releasing Exosomal miR-133a-3p.

Authors:  Xudong Ren; Yu Zhou; Yunling Luo; Chaoqun Wang; Anna Pan; Yanqin Ju; Haoting Sun; Zhifei Lin; Beiyuan Hu; Guangzheng Sun; Wenwei Zhu; Liang Hong
Journal:  Gastroenterol Res Pract       Date:  2022-04-06       Impact factor: 2.260

Review 3.  Non-Coding RNAs and Oral Cancer: Small Molecules With Big Functions.

Authors:  Leila Erfanparast; Mohammad Taghizadieh; Ali Akbar Shekarchi
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

Review 4.  Resveratrol from Dietary Supplement to a Drug Candidate: An Assessment of Potential.

Authors:  Shivani Khattar; Sauban Ahmed Khan; Syed Amir Azam Zaidi; Mahdi Darvishikolour; Uzma Farooq; Punnoth Poonkuzhi Naseef; Mohamed Saheer Kurunian; Mohammed Zaafar Khan; Athar Shamim; Mohd Masih Uzzaman Khan; Zeenat Iqbal; Mohd Aamir Mirza
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.